Long-Term Outcomes and Risk Factor Analysis of Steroid-Refractory Graft versus Host Disease after Hematopoietic Stem Cell Transplantation

Researchers conducted a retrospective study on outcomes and risk factors associated with acute and chronic steroid-refractory graft versus host disease in a large cohort of 1207 patients receiving hematopoietic stem cell transplantation in Saint Louis Hospital between 2007 and 2017.
[Bone Marrow Transplantation]
Abstract
Bookmark

No account yet? Register

0
Share

COVID-19 Cancels Charity Galas and Walks. Science Is Paying the Price

Foundations that fund biomedical research in the United States, the United Kingdom, and elsewhere are reporting record revenue drops because of the pandemic. One major factor: It has forced them to cancel key fundraising events, including glitzy galas, sponsored walks, Broadway partnerships, and more.
[ScienceInsider]
Press Release
Bookmark

No account yet? Register

0
Share

Chromosomal Alterations among Age-Related Hematopoietic Clones in Japan

Scientists describe shared and population-specific patterns of genomic mutations and clonal selection in hematopoietic cells on the basis of 33,250 autosomal mosaic chromosomal alterations that they detected in 179,417 Japanese participants in the BioBank Japan cohort and compared with analogous data from the UK Biobank.
[Nature]
Terao, C., Suzuki, A., Momozawa, Y., Akiyama, M., Ishigaki, K., Yamamoto, K., Matsuda, K., Murakami, Y., McCarroll, S. A., Kubo, M., Loh, P.-R., & Kamatani, Y. (2020). Chromosomal alterations among age-related haematopoietic clones in Japan. Nature, 1–6. https://doi.org/10.1038/s41586-020-2426-2 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Medigene Enters Phase I Clinical Development with Its TCR-T Immunotherapy MDG1021 in Hematological Cancers

Medigene AG has received approval from the Dutch regulatory authority to begin a first clinical trial of MDG1021. MDG1021, which targets the antigen HA-1, thus becomes Medigene’s second proprietary T cell receptor-modified T cell immunotherapy candidate to enter clinical development.
[Medigene AG]
Press Release
Bookmark

No account yet? Register

0
Share

Different Impact of Calreticulin Mutations on Human Hematopoiesis in Myeloproliferative Neoplasms

Mutations of calreticulin were associated with an early clonal dominance at the level of hematopoietic stem and progenitor cells with no significant increase during granulo/monocytic differentiation in most cases.
[Oncogene]
Abstract
Bookmark

No account yet? Register

0
Share

Virtual Lab Tours for Recruitment and Outreach

Virtual lab tours are not new, but they have never been as common as in-person lab tours. However, the pandemic has generated strong incentives for formerly in-person lab tours to go online.
[The Scientist]
Press Release
Bookmark

No account yet? Register

0
Share

Trump to Suspend New Visas for Foreign Scholars

With a proclamation issued on Monday, US President Donald Trump extended and expanded immigration restrictions to limit the entry of foreign workers to the United States. The move set off ripples of alarm among scientists and drew fire from experts concerned about the future of US science.
[Nature News]
Press Release
Bookmark

No account yet? Register

0
Share

Marker Therapeutics Receives USAN Approval for “Zelenoleucel” as Nonproprietary Name for MT-401, Multi-Tumor-Associated Antigen Targeted T Cell Product for Acute Myeloid Leukemia

Marker Therapeutics, Inc. announced that the United States Adopted Names Council has approved “zelenoleucel” as the nonproprietary name for MT-401, a multi-tumor-associated antigen-specific T cell product candidate for the treatment of patients with acute myeloid leukemia following allogeneic stem cell transplant in both adjuvant and active disease settings.
[Marker Therapeutics, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Diaphanous-Related Formin mDia2 Regulates Beta2 Integrins to Control Hematopoietic Stem and Progenitor Cell Engraftment

Scientists showed that loss of diaphanous-related formin mDia2 led to impaired engraftment of long-term hematopoietic stem cells and loss of competitive hematopoietic stem and progenitor cell repopulation.
[Nature Communications]
Mei, Y., Han, X., Liu, Y., Yang, J., Sumagin, R., & Ji, P. (2020). Diaphanous-related formin mDia2 regulates beta2 integrins to control hematopoietic stem and progenitor cell engraftment. Nature Communications, 11(1), 3172. https://doi.org/10.1038/s41467-020-16911-4 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Synthetic Lethal Targeting of TET2-Mutant Hematopoietic Stem and Progenitor Cells (HSPCs) with TOP1-Targeted Drugs and PARP1 Inhibitors

Researchers tested 129 FDA-approved anticancer drugs in a tet2-deficient zebrafish model and showed that topoisomerase 1 (TOP1)-targeted drugs and PARP1 inhibitors selectively killed tet2-mutant HSPCs.
[Leukemia]
Jing, C.-B., Fu, C., Prutsch, N., Wang, M., He, S., & Look, A. T. (2020). Synthetic lethal targeting of TET2 -mutant hematopoietic stem and progenitor cells (HSPCs) with TOP1-targeted drugs and PARP1 inhibitors. Leukemia, 1–15. https://doi.org/10.1038/s41375-020-0927-5 Cite
Abstract
Bookmark

No account yet? Register

0
Share

MLLT10 in Benign and Malignant Hematopoiesis

The authors examine aspects of Mixed Lineage Leukemia Translocated to, 10 (MLLT10), contextualizing its function in benign and malignant hematopoiesis.
[Experimental Hematology]
Deutsch, J. L., & Heath, J. L. (2020). MLLT10 in benign and malignant hematopoiesis. Experimental Hematology, 0(0). https://doi.org/10.1016/j.exphem.2020.06.002 Cite
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share
Share